drugset
drugset / Trial / NCT04903314

Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures

NCT04903314 ↗

Phase 1 Completed 26 enrolled SK Life Science, Inc.
RandomizedSequentialOpen-labelTreatment

Summary

The primary objective of this study is to assess the pharmacokinetics of cenobamate (YKP3089) in pediatric subjects with partial-onset (focal) seizures following single and multiple-dosing.

Timeline

Start
2021-05-27
Primary completion
2025-11-06
Completion
2025-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cenobamate Small molecule 400 mg Oral

Indications

focal epilepsy